Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Dec 20, 2020 12:23pm
248 Views
Post# 32149166

RE:RE:RE:This stock has dropped the whole year

RE:RE:RE:This stock has dropped the whole year
YukonJezza wrote:
it's trading where it was In March. Everything else doubled or tripled and kept their gains. Ate did not. Nice try though


Comparing to other companies works when you're talking about mature companies in similar industries - but - to have expectations about one biotech based on broader market moves is probably useless.  This one will move on its own merits when investors get super-excited.

You either see value in a growth company like this ... or you don't.

You either think this company is going into Phase 3 a winner or you get out because you think it's the end of the road.  You either believe in H2S as a future industry and ATE as the leader in "gaseous mediators" or you don't.  You think their academic studies will make them more desirable or you think it's all "smoke and mirrors."

It's about patience in the process ... as this company proves its worth to others.  That's where ATE is right now.  I have faith in the process, not in an expected annual return.
<< Previous
Bullboard Posts
Next >>